Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review.

ABSTRACT: Breast cancer (BC) is currently the most frequently diagnosed cancer and the primary cause of cancer-related death among women worldwide. Human epidermal growth factor receptor type 2 (HER2)-positive BC accounts for 14.5-15% of all BCs, with a relatively poor prognosis. Neoadjuvant therapy (NAT) has become a preferred treatment option for HER2+ BCs. With the continuous emergence of various clinical trials and new treatment concepts in BC, the NAT model has changed from chemotherapy alone to the neoadjuvant combination of anti-HER2-targeted therapy with chemotherapy, neoadjuvant endocrine therapy, and so on. Therefore, an up-to-date review is needed to inform the selection of NAT strategies for HER2+ BCs. This review was administrated with literature from the PubMed database. Manuscripts we

SUBMITTER: Wang Q 

PROVIDER: S-EPMC9445724 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature